Santos Marc A, Goertz David E, Hynynen Kullervo
Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Theranostics. 2017 Jul 7;7(10):2718-2731. doi: 10.7150/thno.19662. eCollection 2017.
The future of nanomedicines in oncology requires leveraging more than just the passive drug accumulation in tumors through the enhanced permeability and retention effect. Promising results combining mild hyperthermia (HT) with lyso-thermosensitive liposomal doxorubicin (LTSL-DOX) has led to improved drug delivery and potent antitumor effects in pre-clinical studies. The ultimate patient benefit from these treatments can only be realized when robust methods of HT can be achieved clinically. One of the most promising methods of non-invasive HT is the use of focused ultrasound (FUS) with MRI thermometry for anatomical targeting and feedback. MRI-guided focused ultrasound (MRgFUS) is limited by respiratory motion and large blood vessel cooling. In order to translate exciting pre-clinical results to the clinic, novel heating approaches capable of overcoming the limitations on clinical MRgFUS+HT must be tested and evaluated on their ability to locally release drug from LTSL-DOX. In this work, a new system is described to integrate focused ultrasound (FUS) into a two-photon microscopy (2PM) setting to image the release of drug from LTSL-DOX in real-time during FUS+HT . A candidate scheme for overcoming the limitations of respiratory motion and large blood vessel cooling during MRgFUS+HT involves applying FUS+HT to 42°C in short ~30s bursts. The spatiotemporal drug release pattern from LTSL-DOX as a result is quantified using 2PM and compared against continuous (3.5min and 20min at 42°C) FUS+HT schemes and unheated controls. It was observed for the first time that these short duration temperature elevations could produce substantial drug release from LTSL-DOX. Ten 30s bursts of FUS+HT was able to achieve almost half of the interstitial drug concentration as 20min of continuous FUS+HT. There was no significant difference between the intravascular area under the concentration-time curve for ten 30s bursts of FUS+HT and 3.5min of continuous FUS+HT. We have successfully combined 2PM with FUS+HT for imaging the release of DOX from LTSL-DOX in real-time, which will permit the investigation of FUS+HT heating schemes to improve drug delivery from LTSL-DOX. We have evaluated the ability to release DOX in short 30s FUS+HT bursts to 42°C as a method to overcome limitations on clinical MRgFUS+HT and have found that such exposures are capable of releasing measurable amounts of drug. Such an exposure has the potential to overcome limitations that hamper conventional MRgFUS+HT treatments in targets that are associated with substantial tissue motion.
肿瘤纳米药物的未来不仅仅需要借助增强渗透和滞留效应使药物被动积聚在肿瘤中。在临床前研究中,将温和热疗(HT)与溶菌热敏脂质体阿霉素(LTSL-DOX)相结合取得了有前景的结果,实现了更好的药物递送和强大的抗肿瘤效果。只有当临床上能够实现可靠的热疗方法时,患者才能最终从这些治疗中受益。最有前景的非侵入性热疗方法之一是使用聚焦超声(FUS)并结合MRI温度测量进行解剖定位和反馈。MRI引导的聚焦超声(MRgFUS)受到呼吸运动和大血管散热的限制。为了将令人兴奋的临床前研究成果转化到临床,必须测试和评估能够克服临床MRgFUS+HT局限性的新型加热方法,以及它们从LTSL-DOX局部释放药物的能力。在这项工作中,描述了一种新系统,该系统将聚焦超声(FUS)集成到双光子显微镜(2PM)设置中,以在FUS+HT过程中实时成像LTSL-DOX中药物的释放。一种克服MRgFUS+HT过程中呼吸运动和大血管散热限制的候选方案是在约30秒的短脉冲中将FUS+HT应用于42°C。由此产生的LTSL-DOX的时空药物释放模式通过2PM进行量化,并与连续(42°C下3.5分钟和20分钟)FUS+HT方案以及未加热对照进行比较。首次观察到,这些短时间的温度升高能够使LTSL-DOX大量释放药物。十次30秒的FUS+HT脉冲能够达到连续20分钟FUS+HT产生的间质药物浓度的近一半。十次30秒的FUS+HT脉冲和连续3.5分钟FUS+HT在浓度-时间曲线下的血管内面积没有显著差异。我们成功地将2PM与FUS+HT相结合,实时成像LTSL-DOX中阿霉素的释放,这将有助于研究FUS+HT加热方案以改善LTSL-DOX的药物递送。我们评估了在短30秒FUS+HT脉冲至42°C下释放阿霉素的能力,以此作为克服临床MRgFUS+HT局限性的一种方法,发现这种暴露能够释放可测量量的药物。这种暴露有可能克服阻碍传统MRgFUS+HT治疗与大量组织运动相关靶点的局限性。